Project Grant W81XWH0910379

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

Award Summary This Phase I Small Business Innovation Research (SBIR) grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 24, 2025, provides $353,009 to Paramita Therapeutics Inc. to develop novel multivalent prostate-specific membrane antigen (PSMA)-targeted taxane drug conjugates for treating bone metastases in prostate cancer. The project, led by Principal Investigator Sang Van, focuses on synthesizing and evaluating these...

Grant Award Summary The National Cancer Institute (NCI) awarded a $450,904 Project Grant to the Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. The funded project will develop a novel single-cell (phospho-)proteomics platform designed to characterize tumor microenvironment (TME) components—including cancer cells, immune cells, and stromal...

This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...

Federal Grant Award Summary The University of Pittsburgh received a $658,492 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 18, 2026, through February 28, 2031. This award supports research and development of a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC), including castration-resistant prostate cancer adenocarcinoma (CRPC-ADENO) and neuroendocrine prostate...

Federal Project Grant Award Summary Isoprene Pharmaceuticals, Inc. received a $1,022,522 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on June 4, 2025, to support the development of VNPP433-3B (3B) as a novel therapeutic candidate for all stages of prostate cancer. The project, which extends through May 31, 2027, focuses on advancing next-generation galeterone analogs that simultaneously target F-AR/AR-V7 and MNK1/2-EIF4E...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...

Federal Grant Award Summary The National Cancer Institute awarded The Regents of the University of California, San Francisco (UCSF) a $575,178 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period of May 15, 2026 through April 30, 2031. The research project develops novel radiopharmaceutical agents termed "Restricted Interaction Peptides" (RIPs) designed to improve targeted radiotherapy outcomes for metastatic castration-resistant prostate...